Evaluating Study Drug BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Recruiting
18 years - 99 years
All
10 participants needed
1 Location
Brief description of study
This study is being done to test the safety, effectiveness, and side effects of 2 different doses of the study drug, BI 1015550, when compared to taking a placebo, in subjects with PF-ILD. In this study you will either get the active study drug, BI 1015550 or a placebo.
If you join this study, there will be a Screening Period, a Study Drug Period, an End of Treatment Visit, and a Follow-up Period.
Participants will be paid $150 for all study visits.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Lung Disease
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 852132